Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock crash, with a drop exceeding 70% due to regulatory actions from the Hong Kong Stock Exchange regarding its operational viability and asset value [2][5][9]. Company Announcement - On November 14, 2025, Starcoin Group received a notification from the Hong Kong Stock Exchange stating that it failed to maintain sufficient operational levels and asset value, leading to a suspension of its shares on November 26, 2025, unless a review is requested [4][6]. - The company announced that a planned share placement of up to 145 million shares at HKD 0.415 per share has become void due to unmet conditions by September 11, 2025, terminating all responsibilities between the placement agent and the company [2][7]. Financial Performance - For the fiscal year ending March 31, 2025, Starcoin Group reported a revenue of HKD 2.091 million, a decline of 68.28% year-on-year, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [10]. - The basic earnings per share for the reporting period was -HKD 0.2001, with a net cash outflow from operating activities of HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [10]. Company Background - Starcoin Group operates in the pharmaceutical and biotechnology sector, with five divisions including genetic testing services, bioproduct distribution, beauty equipment trade, securities investment, and research on oral insulin products [9]. - The company had previously seen a significant stock price increase of nearly 100% during June to July 2025 before entering a downward trend [9].

Core Viewpoint - Star Chain Group (00399.HK) experienced a significant decline in its stock price, dropping over 70% in early trading, with a current decrease of 66.81%, trading at 0.079 HKD, and a transaction volume of 7.6626 million HKD [1] Company Summary - Star Chain Group's stock price fell by more than 70% in early trading [1] - As of the latest update, the stock is down 66.81% [1] - The current trading price is 0.079 HKD [1] - The total transaction volume reached 7.6626 million HKD [1]

Core Viewpoint - Xing Tai Chain Group (00399) experienced a significant decline in stock price, dropping over 70% in early trading, with a current price of 0.079 HKD and a trading volume of 7.6626 million HKD [1] Group 1: Stock Performance - The company's stock fell by 66.81% as of the latest report [1] - The trading volume reached 7.6626 million HKD, indicating heightened market activity [1] Group 2: Regulatory Announcement - The company received a letter from the Stock Exchange on November 14, 2025, stating that it failed to maintain sufficient operational levels and asset value to support continued listing [1] - According to Listing Rule 6.01(3), trading of the company's shares will be suspended on November 26, 2025, unless the company applies for a review of this decision [1] - The board of directors has decided to request a review of the decision and is preparing the necessary documentation [1] Group 3: Investor Advisory - The company has informed shareholders and potential investors about its decision to seek a review of the suspension [1] - The outcome of the review by the Listing Committee remains uncertain [1]

经审阅该决定函件，公司董事会已决定要求将该决定提交上市委员会复核，并正在编制相关要求函件。 谨此提醒股东及潜在投资者，公司已决定要求复核该决定，惟上市委员会对有关复核的结果并不明朗。 智通财经APP获悉，星太链集团(00399)早盘跌超70%，截至发稿，跌66.81%，报0.079港元，成交额 766.26万港元。 消息面上，星太链集团今早公告，于2025年11月14日，公司接获联交所的函件，通知公司其作出的决 定，即经考虑联交所可得资料(包括公司的提呈文件)，根据第13.24条的规定，公司未能维持足够的运营 水平和足够价值的资产支持其运营，令其股份得以继续上市，并将根据上市规则第6.01(3)条，于2025年 11月26日暂停公司股份买卖，除非公司根据其在第2B章项下的权利申请复核该决定。 ...

Core Viewpoint - The stock of Star Chain Group experienced a significant drop of over 60% upon opening on November 17, 2025, due to a decision from the Hong Kong Stock Exchange regarding insufficient operational levels and asset value [1] Group 1 - The company received a notice from the Stock Exchange on November 14, 2025, indicating that trading of its shares will be suspended on November 26, 2025 [1] - The board of directors has decided to request a review of this decision by the Listing Committee and is preparing the necessary documentation [1]

Core Viewpoint - Star Chain Group (00399.HK) has received a letter from the Stock Exchange indicating that it has failed to maintain sufficient operational levels and asset value to support its operations, leading to a decision to suspend trading of its shares on November 26, 2025, unless a review is requested [1] Group 1 - The Stock Exchange's decision is based on the company's inability to meet the requirements under Rule 13.24 [1] - The company’s board has decided to request a review of the decision by the Listing Committee and is preparing the necessary documentation [1]

Core Viewpoint - Xing Tai Chain Group (00399) has received a letter from the Stock Exchange indicating that it has failed to maintain sufficient operational levels and asset value to support its operations, leading to a decision to suspend trading of its shares on November 26, 2025, unless a review is requested [1] Summary by Sections - Company Operations - The company has been notified by the Stock Exchange that it does not meet the operational and asset value requirements as per Rule 13.24 [1] - The decision to suspend trading is based on the company's inability to maintain adequate operational levels [1] - Share Trading - Trading of the company's shares will be suspended on November 26, 2025, according to Listing Rule 6.01(3) [1] - The company is preparing a request to have this decision reviewed by the Listing Committee [1] - Investor Communication - The company has informed shareholders and potential investors about the decision and its intention to seek a review [1] - The outcome of the review by the Listing Committee remains uncertain [1]

Core Viewpoint - The company, Star Chain Group (00399), has received a letter from the Stock Exchange indicating that it has failed to maintain sufficient operational levels and asset value to support its operations, leading to a decision to suspend trading of its shares on November 26, 2025, unless a review is requested [1] Group 1 - The Stock Exchange's decision is based on the company's inability to meet the requirements outlined in Rule 13.24 [1] - The company’s board has decided to request a review of the Stock Exchange's decision and is preparing the necessary documentation for this request [1] - The outcome of the review by the Listing Committee remains uncertain [1]

STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 聯交所根據第13.24條作出之決定 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告由星太鏈集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）根 據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09條 及香港法例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上 市規則）作出。 於二零二五年十一月十四日，本公司接獲聯交所之函件（「該函件」），通知本公 司其作出之決定，即經考慮聯交所可得資料（包括本公司的提呈文件），根據第 13.24條的規定，本公司未能維持足夠的運營水平和足夠價值的資產支持其運營， 令其股份得以繼續上市，並將根據上市規則第6.01(3)條，於二零二五年十一月 二十六日暫停本公司股份買賣（「該決定」），除非本公司 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 星太鏈集團有限公司 呈交日期: 2025年11月5日 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00399 | 說明 | 星太鏈集團 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000 ...